

Product Name	: EDP-305
Cat. No.	: PC-38044
CAS No.	: 1933507-63-1
Molecular Formula	: C ₃₆ H ₅₈ N ₂ O ₅ S
Molecular Weight	: 630.93
Target	: Farnesoid X Receptor (FXR)
Solubility	: 10 mM in DMSO



Biological Activity

EDP-305 (EDP305) is a potent, selective, nonbile acid **farnesoid X receptor (FXR)** agonist with EC₅₀ of 34 nM, shows antifibrotic effect.

EDP-305 displays antifibrotic effect in rodent models of cholestatic and fatty liver injury: bile duct ligation (BDL) in rats and choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) in mice.

EDP-305 dose-dependently decreases macrophage infiltration and proinflammatory cytokine gene expression.

EDP-305 also dose-dependently reduces interstitial fibrosis and kidney hydroxyproline levels.

EDP-305 decreases TGF-β1-induced YAP nuclear localization in human kidney 2 cells by increasing inhibitory YAP phosphorylation.

EDP-305 reduces interstitial renal fibrosis in a mouse model of unilateral ureteral obstruction.

References

Erstad DJ, et al. Hepatol Commun. 2018 May 21;2(7):821-835.

Li S, et al. FASEB J. 2019 Jun;33(6):7103-7112.

An P, et al. Liver Int. 2020 Jul;40(7):1655-1669.

Ratziu V, et al. J Hepatol. 2022 Mar;76(3):506-517.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com
